Rallybio closed at $15.71 on Nov 4, down 0.98%, 8.8% below its 52-week closing high. Volume of 52.1K shares was 2.02× its 20-day average (well above normal).
Split-adjusted performance: -8.1% over one month, +7.9% over six months, +193.8% over one year.
Short interest was 41.0K shares at the Oct 15 settlement, down 16.8% from the prior report (1.6% of float, 7.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RLYBRallybio | $15.71 | −0.98% | +7.9% | −100.0% | — | 3.2 | $84.6M | |
| GNLXGenelux | $1.94 | +1.04% | −32.4% | — | — | — | $87.8M | Compare |
| TNXPTonix Pharmaceuticals Holding | $5.18 | −0.19% | −64.7% | +577.9% | −299.4% | — | $88.8M | Compare |
| NTHINeOnc Technologies Holdings | $3.10 | +0.98% | −41.6% | — | — | — | $89.3M | Compare |
| PLYXPolaryx Therapeutics | $1.80 | +4.05% | −52.6% | — | — | — | $89.7M | Compare |
| PDSBPDS Biotechnology | $1.28 | −9.22% | +20.8% | — | — | — | $92.8M | Compare |
| FTLFFitLife Brands | $8.18 | +3.68% | −12.1% | +64.6% | 7.3% | 12.3 | $76.8M | Compare |
| LFVNLifevantage Corporation Common Stock (Delaware) | $6.01 | +4.34% | +0.2% | −23.1% | 3.0% | 14.9 | $75.7M | Compare |
| MISTMilestone Pharmaceuticals | $0.7687 | +1.24% | −61.0% | — | −5118.8% | — | $95.7M | Compare |
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
